Independent Research set a €120.00 ($142.86) price target on Bayer (FRA:BAYN) in a report released on Friday. The firm currently has a neutral rating on the healthcare company’s stock.
A number of other research analysts have also recently commented on BAYN. Commerzbank set a €124.00 ($147.62) price objective on Bayer and gave the stock a buy rating in a research note on Friday, September 15th. equinet set a €118.00 ($140.48) price objective on Bayer and gave the stock a buy rating in a research note on Friday, September 15th. Jefferies Group set a €132.00 ($157.14) price objective on Bayer and gave the stock a buy rating in a research note on Monday, September 18th. Baader Bank set a €140.00 ($166.67) target price on Bayer and gave the stock a buy rating in a research report on Wednesday, September 20th. Finally, Warburg Research set a €121.00 ($144.05) target price on Bayer and gave the stock a buy rating in a research report on Wednesday, September 20th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and fourteen have assigned a buy rating to the stock. The stock currently has an average rating of Buy and an average target price of €122.33 ($145.63).
Bayer (FRA BAYN) opened at €104.44 ($124.33) on Friday. The company has a market capitalization of $86,250.00 and a PE ratio of 28.00. Bayer has a one year low of €99.69 ($118.68) and a one year high of €123.82 ($147.40).
ILLEGAL ACTIVITY WARNING: “Independent Research Analysts Give Bayer (BAYN) a €120.00 Price Target” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/01/15/independent-research-analysts-give-bayer-bayn-a-120-00-price-target.html.
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and womens health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.